AI-Designed Universal Coronavirus Vaccine Successfully Completes Phase 1 Clinical Trial Researchers from the University of Cambridge and its spinout company DIOSynVax have successfully completed the first-in-human trial of an AI-designed universal coronavirus vaccine. The study, conducted across clinical research facilities in Southampton and Cambridge, demonstrated that the experimental immunization is safe and well-tolerated while eliciting broad immune responses against multiple members of the Sarbecovirus family. The trial involved 39 healthy adults aged 18 to 50. Unlike conventional vaccines that target specific circulating strains, this candidate utilizes an AI-generated super-antigen. For the first time, the active component was engineered entirely through computational modeling and machine learning. By analyzing genomic data from global surveillance programs, the algorithm identified conserved structural features across Sarbecoviruses and integrated them into a single antigen. This approach aims to provide lasting protection against known pathogens, including SARS-CoV-2 and SARS, as well as emerging bat coronaviruses with zoonotic potential. Trial results confirmed no significant adverse events. The super-antigen was administered via a needle-free microfluidic jet system using a DNA vaccine platform, a delivery method chosen to streamline large-scale immunization campaigns and improve patient compliance. Preclinical animal models previously indicated robust cross-reactive immunity, a finding now substantiated in human subjects. The findings were recently published in the Journal of Infection. This milestone marks a fundamental shift from reactive to proactive vaccine development. Traditional influenza and coronavirus boosters require frequent reformulation to match evolving viral mutations. By targeting conserved viral architectures, the Cambridge technology is designed to maintain efficacy across variants and related species. Lead researcher Professor Jonathan Heeney noted that the platform effectively breaks the cycle of variant chasing, while trial chief investigator Professor Saul Faust emphasized that deploying such universal candidates ahead of an outbreak could prevent widespread transmission, reduce societal disruption, and preserve economic stability. DIOSynVax, founded in 2017 with support from Cambridge Enterprise and primarily funded by Innovate UK, will now advance the candidate to a larger Phase 2 trial. This next phase will assess immunogenicity in a more diverse population and further validate the breadth of protection. The AI super-antigen architecture is also being adapted for other high-priority families, including influenza and filoviruses like Ebola. Professor Marian Knight of the NIHR highlighted the success as a pivotal advancement in public health infrastructure, underscoring the critical role of academic-industry partnerships in accelerating clinical translation. While regulatory approval and commercial deployment remain years away, the trial establishes a viable blueprint for next-generation immunizations. By decoupling vaccine design from real-time viral surveillance, researchers have demonstrated a scalable pathway to future-proof global health defenses against rapidly evolving pathogens.